Want to Participate in Cutting-Edge Brain Research?
Contact us today for eligibility screening and consultation.
Pre-IND randomized, double-blind, placebo-controlled study investigating a novel cognitive-enhancement intervention for adults with early signs of cognitive decline.
Currently Recruiting
Advancing brain health through rigorous, ethical, and innovative clinical research.
This pre-IND clinical trial (NCT07214974) evaluates the safety and efficacy of a novel non-invasive cognitive-enhancement protocol in adults aged 55–75 with mild cognitive impairment (MCI) or early age-related cognitive decline. Noah Tech provides certified MoCA administration, standardized cognitive assessments, and data-management support.
Conditions: Mild Cognitive Impairment, Age-Related Cognitive Decline.
Intervention: Novel cognitive-enhancement protocol vs. placebo.
Design: Randomized, double-blind, placebo-controlled, parallel assignment.
Change in Montreal Cognitive Assessment (MoCA) score from baseline to Week 12.
Secondary outcomes include executive function, memory performance, and safety/tolerability.
To learn more or check eligibility, visit the official listing: clinicaltrials.gov/study/NCT07214974.
Or contact our team directly: info@noahtech.life.